U.S., July 26 -- ClinicalTrials.gov registry received information related to the study (NCT07085559) titled 'Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research' on July 14.
Brief Summary: A Study of Metabolically Armed BCMA CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Plasma Cell Neoplasms.
Study Start Date: June 23
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma (MM)
Plasma Cell Leukemia (PCL)
AL Amyloidosis (AL)
Intervention:
DRUG: Metabolically Armed BCMA CAR-T cells.
Each subject receive metabolically armed BCMA CAR- T cells by intravenous infusion.
Recruitment Status: RECRUITING
Sponsor: Anhui Provincial Hospital...